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Case 1
A 62-year-old nonsmoker man who suffered from a weight loss
of 2 kg in 2 months was found to have lung adenocarci-
noma with multiple metastases. He received gefitinib (Iressa;
AstraZeneca, Wilmington, DE) 250 mg/d as a first-line treat-
ment. Excellent response to gefitinib is noted in his fourth week
of treatment. However, fever, dry cough, and dyspnea developed
in the sixth week of gefitinib treatment. Pulse oximetry showed
a 84% oxyhemoglobin saturation, whereas chest computed to-
mography revealed bilateral ground-glass opacities (Figure 1A).
Gefitinib was discontinued immediately, and methylpred-
nisolone 1.77mg/kg/d was initiated. There was no clinical evi-
dence of tumor progression. No pathologic microorganism was
isolated in both sputum and blood cultures, and serology test
results for Mycoplasma pneumoniae, Chlamydia pneumoniae,
and Legionella pneumophila were all negative.
There was clinical improvement on the sixth day of
steroid therapy and erlotinib (Tarceva; Genentech, OSI Phar-
maceuticals, Melville, NY) 150 mg/d was administered con-
currently. No pulmonary toxicity recurred because the erlo-
tinib rechallenge and partial tumor remission was achieved
(Figure 1B). Progressive disease with leptomeningeal metas-
tasis was documented 7 months later.
Case 2
A 77-year-old nonsmoker woman had exertional dyspnea
for 1 year. She was found to have adenocarcinoma of right upper
lung, with lung to lung metastasis. Gefitinib (250 mg/d) was
administered as a first-line treatment. During the follow-up,
tumor size decreased under treatment. In the seventh week of
treatment, dry cough and progressive dyspnea developed. Hy-
poxemia and 93% of oxyhemoglobin saturation was found.
Chest computed tomography revealed partial remission of RUL
tumor and extensive bilateral ground-glass opacities (Figure 2A).
Gefitinib was immediately discontinued, and methylpred-
nisolone 2.42 mg/kg/d was initiated. No pathologic microorgan-
ism was isolated in both sputum and blood cultures, whereas
serology test results for atypical pathogens were all negative.
There was clinical improvement by the third day of steroid
therapy. Six weeks after interstitial lung disease, Erlotinib 100
mg/d was administered concurrently with prednisolone 10 mg/d.
No pulmonary toxicity recurred and partial remission was
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FIGURE 1. A, Chest computed tomography (CT) showed
diffuse ground-glass opacity over lower lung zones (arrows)
and pleural effusion on the sixth week of gefitinib therapy.
B, Chest CT performed on 48th day of erlotinib therapy
showed multiple small residual lung tumors.
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achieved (Figure 2B). Disease progression was documented 8
months later.
DISCUSSION
Compared with platinum-based chemotherapy, adverse
effects of gefitinib are modest.1 However, ILD is an infre-
quent but a life-threatening pulmonary toxicity.2 The inci-
dence of ILD during gefitinib treatment is up to 2% in
Japanese and 1% worldwide.3
Once ILD occur, immediate withdrawal of gefitinib is
recommended.4 An approximately 30 to 40% mortality rate
could be attributable to this serious adverse effect.2 Because
ILD tends to happen in the first 4 weeks,2 it always leads to
premature termination of treatment.
Erlotinib, another epidermal growth factor receptor-ty-
rosine kinase inhibitor, has a similar chemical structure as that of
gefitinib. In the BR.21 trial, the incidence of ILD is 0.8% and the
rates are similar in the erlotinib and placebo groups.5
The precise mechanism of ILD induced by gefitinib or
erlotinib remains unknown. Because the potency of erlotinib
150 mg/d is superior to gefitinib 250 mg/d, the development
of ILD seems not related to drug potency.
In conclusion, there are two cases of gefitinib-associ-
ated pulmonary toxicity subsequently treated with erlotinib.
But we must highlight the risk of ILD with another similar
epidermal growth factor receptor-tyrosine kinase inhibitor.
The patient should be carefully informed of this high-fatality
complication before rechallenge.
REFERENCES
1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel
in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
2. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese
patients with lung cancer. Am J Respir Crit Care Med 2008;177:1348–1357.
3. ArmourA.Gefitinib in advanced non-small cell lung cancer: clinical experience
in patients of Asian origin. Asia Pac J Clin Oncol 2007;3:366–378.
4. Kataoka K, Taniguchi H, Hasegawa Y, et al. Interstitial lung disease
associated with gefitinib. Respir med 2006;100:698–704.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; the National Cancer
Institute of Canada Clinical Trials Group. Erlotinib in previously treated
non-small cell lung cancer. N Engl J Med 2005;353:123–132.
FIGURE 2. A, The chest computed tomography (CT)
showed decreased size of the main tumor (thick arrow) and
diffuse ground-glass opacity over upper lung zones (thin ar-
rows) on the seventh week of gefitinib therapy. B, The chest
CT performed on the 131th day of erlotinib therapy showed
partial remission of right upper lung tumor (arrow).
Chang et al. Journal of Thoracic Oncology • Volume 5, Number 7, July 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1106
